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Background: The impact of Appropriate Use Criteria (AUC) on the cost effectiveness of SPECT myocardial perfusion imaging (MPI)and associated 
subsequent downstream testing and interventions in the community setting has not been evaluated.
Methods: In a cohort study of 1511 patients who underwent outpatient, community-based MPI, we determined adherence to the 2009 AUC, 
categorizing referrals into appropriate/uncertain vs. inappropriate groups. Patients were followed prospectively for 27 ± 10 months for major 
adverse cardiac events (MACE), defined as cardiac death or myocardial infarction, and revascularization within 6 months of MPI. Total cost incurred 
per patient from MPI, subsequent consultations, cardiac catheterization, revascularization and subsequent antiplatelet therapy for one year was 
calculated using the 2012 Medicare national average reimbursement.
results: The total cost incurred for the entire cohort was $1,637,977: $955,313 for the 823 (54.5%) patients with appropriate/uncertain use 
and $682,644 for the 688 (45.5%) patients with inappropriate use. The mean cost per patient with appropriate use was $1,161 ± 2,189 vs. $992 
± 1,418 for patients with inappropriate use (Mann-Whitney test P <0.001). MPI accurately identified the need for coronary revascularization within 
6 months in 14 (1.7%) patients in the appropriate/uncertain use group vs. 7 (1.0%) in the Inappropriate group (P =0.258), with a respective cost 
of $68,237 and $97,523 per patient. MPI accurately predicted MACE in 8 (1.0%) patients with appropriate/uncertain use vs. 1 (0.1%) patient with 
inappropriate MPI (p = 0.04); the annualized cost per one MACE predicted was $268,682 vs. $1,535,995 with inappropriate use.
conclusion: The cost associated with Inappropriate MPI use was nearly 1.5 times that of Appropriate/Uncertain use for accurately predicting 
each subsequent revascularization within 6 months, while the cost of one accurate MACE prediction was nearly 6 fold higher than patients with 
Appropriate/Uncertain use. Inappropriate use appears to severely impair the cost effectiveness of MPI in risk stratification.
